Saint John’s Cancer Institute
  • Home
  • About Us
    • About Us
    • Blog
    • Cancer Innovation Newsletter
    • Directory & Phone Number
    • Events
    • In the News
    • Patents & Innovations
    • Research Administration
    • Saint John’s Health Center
    • Saint John’s Health Center Foundation
    • Webinars
  • Centers of Excellence
    • Center’s Of Excellence Video Overview
    • Brain Tumors & Neuroscience
    • Breast Surgery and Oncology
    • Endocrine Tumors and Disorders
    • Gastrointestinal and Hepatobiliary Tumors
    • Gynecologic Oncology
    • Head and Neck Oncology
    • Melanoma, Skin and Soft Tissue Tumors
    • Pathology
    • Thoracic Surgical Oncology
    • Translational Research Departments
    • Urology and Urologic Oncology
  • Fellowship Programs
    • Fellowship Overview
    • Breast Surgical Oncology Fellowship
    • Donald L. Morton Complex General Surgical Oncology Fellowship
    • Neurosurgery Fellowship
    • Urology Fellowship
    • Translational Molecular Medicine Fellowship
    • Philanthropy Sponsored Programs
  • Clinical Trials
    • Active Clinical Trials
    • Clinical Trials FAQs
    • COVID-19 Research at Saint John’s Health Center and Saint John’s Cancer Institute
    • Participate In A Clinical Trial
  • Cancer Support Services
    • Meet our Team
    • Psychiatry
    • Social Work
    • Nutrition
    • Survivorship
    • Palliative Care
    • Rehabilitation
    • Genetics
    • Bone Health
    • Spiritual Care
    • Ongoing Providence Saint John’s Classes and Groups
    • Inspiring Stories
    • Supportive Care Research
    • Patient and Caregiver Resources
  • Contact Us
    • Directory & Phone Number
    • Maps & Directions
    • Out-of-Town & International Patients
  • My Chart
  • Search
  • Donate Now

Hematologic Cancer Clinical Trials

Clinical Trials Hematologic Cancer Clinical Trials

Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subjects with follicular lymphoma.

Learn More

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subjects with follicular lymphoma.

Learn More

I Want To:

Request an Appointment
Enter a Fellowship
Participate In A Clinical Trial
Donate Now
Careers

Connect With Us:

Locations Map
Contact Us
Main Facility Phone
310-315-6125
Providence Resource Line
888-432-5464

  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • YouTube

About Saint John’s Cancer Institute

Saint John’s Cancer Institute is a renowned research facility dedicated to advanced therapeutics, translational science, and best practices. We support fellowships and clinical trials, collaborating with industry and academic partners worldwide.

Administrative Office & Research Center:
2200 Santa Monica Blvd.
Santa Monica, CA 90404
Cancer Clinic:
Providence Saint John’s Health Center
2121 Santa Monica Blvd.
Santa Monica, CA 90401

©2022 Saint John’s Cancer Institute. All Rights Reserved. Site Map